They aren't the only ones. There's a laundry list of companies pushing to trial something.
I may be wrong in my assumption so please correct me if I am. I think the benefit of MPL is that it regulates the mTOR pathway which decreases infectivity and should actually enhance the effectiveness of a drug that would directly treat Covid-19. So to my understanding MPL used in combination with another drug would be the answer.
Ann: PharmAust Shareholder Update, page-127
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
-0.005(2.86%) |
Mkt cap ! $82.69M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.0¢ | 17.0¢ | $55.34K | 315.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 537417 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 88847 | 4 |
View Market Depth
| Last trade - 16.10pm 09/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |